Cargando…

Combination therapeutics of Nilotinib and radiation in acute lymphoblastic leukemia as an effective method against drug-resistance

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is characterized by a very poor prognosis and a high likelihood of acquired chemo-resistance. Although tyrosine kinase inhibitor (TKI) therapy has improved clinical outcome, most ALL patients relapse following treatment with T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaveh, Kamran, Takahashi, Yutaka, Farrar, Michael A., Storme, Guy, Guido, Marcucci, Piepenburg, Jamie, Penning, Jackson, Foo, Jasmine, Leder, Kevin Z., Hui, Susanta K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500007/ https://www.ncbi.nlm.nih.gov/pubmed/28683103 http://dx.doi.org/10.1371/journal.pcbi.1005482

Ejemplares similares

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Inhibition of MDM2 by Nilotinib Contributes to Cytotoxicity in Both Philadelphia-Positive and Negative Acute Lymphoblastic Leukemia
por: Zhang, Hailong, et al.
Publicado: (2014)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Targeting miR-126 in Ph+ acute lymphoblastic leukemia
por: Qiao, Junjing, et al.
Publicado: (2023)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation
por: Farnsworth, Paul, et al.
Publicado: (2012)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Optimized Treatment Schedules for Chronic Myeloid Leukemia
por: He, Qie, et al.
Publicado: (2016)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
por: Piccaluga, Pier Paolo, et al.
Publicado: (2012)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
por: Patel, Vihang, et al.
Publicado: (2017)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia
por: Arora, Geetika, et al.
Publicado: (2022)

Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
por: Onaka, Takashi, et al.
Publicado: (2017)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia
por: Ismail, Abdel-Latif S, et al.
Publicado: (2020)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
por: Al-Dubai, Husam N., et al.
Publicado: (2020)

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
por: Chahal, Kirti Kandhwal, et al.
Publicado: (2019)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

Radiation-induced hypopituitarism in children with acute lymphoblastic leukemia
por: Mirouliaei, Mehrdad, et al.
Publicado: (2013)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report
por: Caocci, Giovanni, et al.
Publicado: (2014)

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
por: Sanford, David, et al.
Publicado: (2014)

Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
por: Kong, Yuan, et al.
Publicado: (2017)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
por: Cengiz Seval, Güldane, et al.
Publicado: (2017)

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia
por: Kiriyama, Hiroyuki, et al.
Publicado: (2019)

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
por: Airiau, K, et al.
Publicado: (2013)

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
por: Takahashi, Naoto, et al.
Publicado: (2014)

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
por: Aldoss, Ibrahim, et al.
Publicado: (2018)

Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?
por: Capuozzo, Maurizio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a78d47ho3obtap3sa2oqqgpldt